DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Patten & Patten Inc. TN

Patten & Patten Inc. TN lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 5.0% in the fourth quarter, HoldingsChannel reports. The firm owned 74,811 shares of the medical device company’s stock after buying an additional 3,570 shares during the period. Patten & Patten Inc. TN’s holdings in DexCom were worth $5,818,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Harbour Investments Inc. increased its holdings in shares of DexCom by 8.8% during the 3rd quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company’s stock worth $864,000 after buying an additional 1,046 shares during the last quarter. GSA Capital Partners LLP increased its stake in DexCom by 129.1% during the third quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company’s stock worth $688,000 after acquiring an additional 5,787 shares during the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in DexCom in the third quarter valued at $654,000. Aigen Investment Management LP acquired a new position in shares of DexCom in the 3rd quarter valued at $349,000. Finally, Metis Global Partners LLC grew its holdings in shares of DexCom by 14.5% during the 3rd quarter. Metis Global Partners LLC now owns 21,166 shares of the medical device company’s stock worth $1,419,000 after purchasing an additional 2,684 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Up 3.2 %

Shares of NASDAQ:DXCM opened at $70.69 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm’s 50 day moving average price is $83.99 and its 200 day moving average price is $76.89. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $27.62 billion, a price-to-earnings ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,657 shares of company stock worth $8,019,422 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.